Understanding the Mechanisms of Proteinuria: Therapeutic Implications

被引:29
作者
Toblli, Jorge E. [1 ,2 ]
Bevione, P. [2 ]
Di Gennaro, F. [3 ]
Madalena, L. [1 ,4 ]
Cao, G. [1 ]
Angerosa, M. [1 ,4 ,5 ]
机构
[1] Univ Buenos Aires, Fac Med, Hosp Aleman, Lab Med Expt, Ave Pueyrredon 1640, RA-1118 Buenos Aires, DF, Argentina
[2] Hosp Aleman, Serv Nefrol, RA-1118 Buenos Aires, DF, Argentina
[3] Hosp Aleman, Dept Med Interna, RA-1118 Buenos Aires, DF, Argentina
[4] Univ Buenos Aires, Fac Farm & Bioquim, Dept Bioquim Clin, RA-1113 Buenos Aires, DF, Argentina
[5] Univ Buenos Aires, Hosp Clin Jose de San Martin, RA-1120 Buenos Aires, DF, Argentina
关键词
D O I
10.1155/2012/546039
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A large body of evidence indicates that proteinuria is a strong predictor of morbidity, a cause of inflammation, oxidative stress and progression of chronic kidney disease, and development of cardiovascular disease. The processes that lead to proteinuria are complex and involve factors such as glomerular hemodynamic, tubular absorption, and diffusion gradients. Alterations in various different molecular pathways and interactions may lead to the identical clinical end points of proteinuria and chronic kidney disease. Glomerular diseases include a wide range of immune and nonimmune insults that may target and thus damage some components of the glomerular filtration barrier. In many of these conditions, the renal visceral epithelial cell ( podocyte) responds to injury along defined pathways, which may explain the resultant clinical and histological changes. The recent discovery of the molecular components of the slit diaphragm, specialized structure of podocyte-podocyte interaction, has been a major breakthrough in understanding the crucial role of the epithelial layer of the glomerular barrier and the pathogenesis of proteinuria. This paper provides an overview and update on the structure and function of the glomerular filtration barrier and the pathogenesis of proteinuria, highlighting the role of the podocyte in this setting. In addition, current antiproteinuric therapeutic approaches are briefly commented.
引用
收藏
页数:13
相关论文
共 116 条
  • [1] Significance and Management of Proteinuria in Kidney Transplant Recipients
    Amer, Hatem
    Cosio, Fernando G.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (12): : 2490 - 2492
  • [2] Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation
    Bailey, E
    Bottomley, MJ
    Westwell, S
    Pringle, JH
    Furness, PN
    Feehally, J
    Brenchley, PEC
    Harper, SJ
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (10) : 735 - 738
  • [3] Nephrin and Neph1 co-localize at the podocyte foot process intercellular junction and form cis hetero-oligomers
    Barletta, GM
    Kovari, IA
    Verma, RK
    Kerjaschki, D
    Holzman, LB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (21) : 19266 - 19271
  • [4] Associations among Estimated Glomerular Filtration Rate, Proteinuria, and Adverse Cardiovascular Outcomes
    Bello, Aminu K.
    Hemmelgarn, Brenda
    Lloyd, Anita
    James, Matthew T.
    Manns, Braden J.
    Klarenbach, Scott
    Tonelli, Marcello
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (06): : 1418 - 1426
  • [5] Renal albumin absorption in physiology and pathology
    Birn, H
    Christensen, E
    [J]. KIDNEY INTERNATIONAL, 2006, 69 (03) : 440 - 449
  • [6] Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy
    Bonegio, RGB
    Fuhro, R
    Wang, ZY
    Valeri, CR
    Andry, C
    Salant, DJ
    Lieberthal, W
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07): : 2063 - 2072
  • [7] The Spectrum of MYH9-Associated Nephropathy
    Bostrom, Meredith A.
    Freedman, Barry I.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (06): : 1107 - 1113
  • [8] BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141
  • [9] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [10] Inhibition of MTOR Disrupts Autophagic Flux in Podocytes
    Cina, Davide P.
    Onay, Tuncer
    Paltoo, Aarti
    Li, Chengjin
    Maezawa, Yoshiro
    De Arteaga, Javier
    Jurisicova, Andrea
    Quaggin, Susan E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (03): : 412 - 420